The market for biopharmaceutical products is progressing at a rapid rate in India, given the high demand for such products. The increasing urbanisation of the country, spread of immunisation programmes and better healthcare-related facilities have together boosted the development of the market for b... View more
The market for biopharmaceutical products is progressing at a rapid rate in India, given the high demand for such products. The increasing urbanisation of the country, spread of immunisation programmes and better healthcare-related facilities have together boosted the development of the market for biopharmaceuticals. There is an increasing awareness that biopharmaceuticals may result in a much better way of disease management, thus increasing life expectancy in the process. A number of large domestic as well as multinational companies are increasingly investing in the research and development of biopharmaceutical products. The availability of a technically skilled workforce has further proved to be advantageous for the industry. Hide this
Q3FY13 result of Biocon was moderately better than our estimates. Revenue of the company grew by 24% and EBITDA grew by 18% Y-o-Y. The quarterly outperformance was largely on account of improved performance of Biopharma (ex-licensing income) driven b....
Biopharmaceuticals | Jan 29th, 2013 | by MP Advisors
Zydus today announced the launch of its novel dual PPAR agonist Lipaglyn (saroglitazar) for treatment of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, ....
Biopharmaceuticals | Sep 16th, 2013 | by MP Advisors
US district court (NY Southern) granted a motion by Mylan and Sandoz to dismiss the litigation over 4 non OB patents (938, 802, 359 - expiring in Sept, 2019 and 580 - expiring in Feb - 2020). Together these patents are referred to as Gad Patents. The....
Biopharmaceuticals | Jul 24th, 2013 | by MP Advisors
We reiterate our market perform rating on Cipla with a price target of Rs.415 (20x FY-15 earnings) as we expect
1) Sales growth to slow down in the upcoming quarters FY-2014. The 1Q-FY 14 sales and profit growth were primarily led by one-offs.
....
Biopharmaceuticals | Aug 21st, 2013 | by MP Advisors
We reiterate our outperform rating on Cadila; however, revise our price target down to Rs.950 (20x of FY15 earnings), owing to the delay in the approval of ANDAs. We lower our revenue and EBITDA estimates of FY14 by 5% and 8% respectively as during ....
Biopharmaceuticals | Aug 21st, 2013 | by MP Advisors
